ES2059132T3 - 2'-o-alquil-nucleotidos, asi como polimeros, que contienen tales nucleotidos. - Google Patents
2'-o-alquil-nucleotidos, asi como polimeros, que contienen tales nucleotidos.Info
- Publication number
- ES2059132T3 ES2059132T3 ES91907452T ES91907452T ES2059132T3 ES 2059132 T3 ES2059132 T3 ES 2059132T3 ES 91907452 T ES91907452 T ES 91907452T ES 91907452 T ES91907452 T ES 91907452T ES 2059132 T3 ES2059132 T3 ES 2059132T3
- Authority
- ES
- Spain
- Prior art keywords
- nucleotides
- atom
- different
- same
- possibly modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002773 nucleotide Substances 0.000 title 2
- 229920000642 polymer Polymers 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 239000000178 monomer Substances 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 229910003204 NH2 Inorganic materials 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000006193 alkinyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000002787 antisense oligonuctleotide Substances 0.000 abstract 1
- -1 cyano, carboxy, hydroxy Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000000371 nucleobase group Chemical group 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 229910052711 selenium Inorganic materials 0.000 abstract 1
- 239000007790 solid phase Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Color Electrophotography (AREA)
- Fixing For Electrophotography (AREA)
- Electrophotography Configuration And Component (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4011473 | 1990-04-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2059132T3 true ES2059132T3 (es) | 1994-11-01 |
Family
ID=6404077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES91907452T Expired - Lifetime ES2059132T3 (es) | 1990-04-09 | 1991-04-08 | 2'-o-alquil-nucleotidos, asi como polimeros, que contienen tales nucleotidos. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0524997B1 (fr) |
| JP (1) | JPH07103150B2 (fr) |
| AT (1) | ATE109788T1 (fr) |
| CA (1) | CA2080231C (fr) |
| DE (2) | DE4037363A1 (fr) |
| DK (1) | DK0524997T3 (fr) |
| ES (1) | ES2059132T3 (fr) |
| WO (1) | WO1991015499A1 (fr) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5872232A (en) * | 1990-01-11 | 1999-02-16 | Isis Pharmaceuticals Inc. | 2'-O-modified oligonucleotides |
| US5623065A (en) * | 1990-08-13 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
| US5670633A (en) * | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
| US6005087A (en) * | 1995-06-06 | 1999-12-21 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
| US7101993B1 (en) | 1990-01-11 | 2006-09-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides containing 2′-O-modified purines |
| US5859221A (en) * | 1990-01-11 | 1999-01-12 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
| US5955589A (en) * | 1991-12-24 | 1999-09-21 | Isis Pharmaceuticals Inc. | Gapped 2' modified oligonucleotides |
| US6358931B1 (en) | 1990-01-11 | 2002-03-19 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating RNA |
| US6399754B1 (en) | 1991-12-24 | 2002-06-04 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides |
| US5914396A (en) * | 1990-01-11 | 1999-06-22 | Isis Pharmaceuticals, Inc. | 2'-O-modified nucleosides and phosphoramidites |
| US5514786A (en) * | 1990-01-11 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Compositions for inhibiting RNA activity |
| US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
| US5965722A (en) * | 1991-05-21 | 1999-10-12 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ras gene with chimeric and alternating oligonucleotides |
| US7119184B2 (en) | 1991-08-12 | 2006-10-10 | Isis Pharmaceuticals, Inc. | Oligonucleotides having A-DNA form and B-DNA form conformational geometry |
| US6307040B1 (en) | 1992-03-05 | 2001-10-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
| US5700922A (en) * | 1991-12-24 | 1997-12-23 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
| US5856455A (en) * | 1991-12-24 | 1999-01-05 | Isis Pharmaceuticals, Inc. | Gapped 2'-modified oligonucleotides |
| US6277603B1 (en) | 1991-12-24 | 2001-08-21 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
| JP3131222B2 (ja) | 1991-12-24 | 2001-01-31 | アイシス・ファーマシューティカルス・インコーポレーテッド | ギャップを有する２′修飾オリゴヌクレオチド |
| ATE299509T1 (de) | 1992-07-23 | 2005-07-15 | Isis Pharmaceuticals Inc | Neue 2'-o-alkyl-nukleoside und -phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen |
| TW244371B (fr) * | 1992-07-23 | 1995-04-01 | Tri Clover Inc | |
| US5652355A (en) * | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
| US6346614B1 (en) | 1992-07-23 | 2002-02-12 | Hybridon, Inc. | Hybrid oligonucleotide phosphorothioates |
| GB9304618D0 (en) * | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Chemical compounds |
| PT679657E (pt) * | 1994-04-27 | 2003-11-28 | Novartis Ag | Nucleosidos e oligonucleotidos com grupos 2'-eter |
| GB9417746D0 (en) * | 1994-09-03 | 1994-10-19 | Ciba Geigy Ag | Chemical compounds |
| GB9417938D0 (en) * | 1994-09-06 | 1994-10-26 | Ciba Geigy Ag | Compounds |
| WO1996027606A1 (fr) | 1995-03-06 | 1996-09-12 | Isis Pharmaceuticals, Inc. | Procede ameliore pour la synthese des pyrimidines a substitution 2'-o et de leurs composes oligomeres |
| US6166197A (en) * | 1995-03-06 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
| GB9606158D0 (en) * | 1996-03-23 | 1996-05-29 | Ciba Geigy Ag | Chemical compounds |
| US5856099A (en) * | 1996-05-21 | 1999-01-05 | Isis Pharmaceuticals, Inc. | Antisense compositions and methods for modulating type I interleukin-1 receptor expression |
| CA2256765A1 (fr) | 1996-06-06 | 1997-12-11 | Novartis Ag | Nucleosides substitues en position 2' et derives oligonucleotidiques |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
| US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
| GB9612600D0 (en) | 1996-06-13 | 1996-08-21 | Ciba Geigy Ag | Chemical compounds |
| US6576752B1 (en) | 1997-02-14 | 2003-06-10 | Isis Pharmaceuticals, Inc. | Aminooxy functionalized oligomers |
| US6172209B1 (en) | 1997-02-14 | 2001-01-09 | Isis Pharmaceuticals Inc. | Aminooxy-modified oligonucleotides and methods for making same |
| US6127533A (en) * | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
| WO2000040592A1 (fr) * | 1998-12-30 | 2000-07-13 | Oligos Etc. Inc. | Acides nucleiques a extremites bloquees, squelette modifie et stabilite acide et leurs utilisations therapeutiques |
| AU2003291755A1 (en) | 2002-11-05 | 2004-06-07 | Isis Pharmaceuticals, Inc. | Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use |
| US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
| US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
| US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0260032B1 (fr) * | 1986-09-08 | 1994-01-26 | Ajinomoto Co., Inc. | Composés pour cliver l'ARN dans une position spécifique, oligomères utilisés pour la préparation de ces composés et produits de départ pour la synthèse de ces oligomères |
| US4843066A (en) * | 1986-11-27 | 1989-06-27 | Nippon Zoki Pharmaceutical Co., Ltd. | Novel adenosine derivatives and pharmaceutical composition containing them as an active ingredient |
| FR2632955B1 (fr) * | 1988-06-20 | 1991-12-27 | Oris Ind | Derives de nucleosides utilisables pour la synthese d'oligonucleotides marques, oligonucleotides obtenus a partir de ces derives et leur synthese |
| GB2226027B (en) * | 1988-12-13 | 1992-05-20 | Sandoz Ltd | Adenosine derivatives,their production and use |
| JPH0372493A (ja) * | 1989-08-10 | 1991-03-27 | Kikkoman Corp | ２´―ｏ―置換―アデノシン―３´，５´―環状リン酸又はその塩の製法 |
-
1990
- 1990-11-23 DE DE4037363A patent/DE4037363A1/de not_active Withdrawn
-
1991
- 1991-04-08 EP EP91907452A patent/EP0524997B1/fr not_active Expired - Lifetime
- 1991-04-08 DE DE59102512T patent/DE59102512D1/de not_active Expired - Fee Related
- 1991-04-08 ES ES91907452T patent/ES2059132T3/es not_active Expired - Lifetime
- 1991-04-08 AT AT91907452T patent/ATE109788T1/de not_active IP Right Cessation
- 1991-04-08 CA CA002080231A patent/CA2080231C/fr not_active Expired - Fee Related
- 1991-04-08 WO PCT/EP1991/000665 patent/WO1991015499A1/fr not_active Ceased
- 1991-04-08 JP JP3506857A patent/JPH07103150B2/ja not_active Expired - Fee Related
- 1991-04-08 DK DK91907452.6T patent/DK0524997T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| WO1991015499A1 (fr) | 1991-10-17 |
| DE4037363A1 (de) | 1991-10-10 |
| JPH07103150B2 (ja) | 1995-11-08 |
| DE59102512D1 (de) | 1994-09-15 |
| CA2080231C (fr) | 2000-10-10 |
| JPH05505197A (ja) | 1993-08-05 |
| CA2080231A1 (fr) | 1991-10-10 |
| EP0524997A1 (fr) | 1993-02-03 |
| ATE109788T1 (de) | 1994-08-15 |
| EP0524997B1 (fr) | 1994-08-10 |
| DK0524997T3 (da) | 1995-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2059132T3 (es) | 2'-o-alquil-nucleotidos, asi como polimeros, que contienen tales nucleotidos. | |
| TW291486B (fr) | ||
| NZ520071A (en) | 4-aminopiperidine derivatives and their use as medicine | |
| GB2346879A (en) | Preparation of 3-substituted adenines and imidazo pyridines | |
| NL300159I1 (nl) | Werkwijze voor het verwijderen van galzuren uit een patiënt en gealkyleerde samenstellingen daarvoor. | |
| CA2296642A1 (fr) | Allongeurs de chaine contenant du silicium | |
| ATE154029T1 (de) | 7-deazapurin modifizierte oligonukleotide | |
| PL360880A1 (en) | Use of trioxepans in the process to make high-solid acrylic, styrenic, and ldpe-type resins | |
| IL103365A0 (en) | Latent thiol mercaptan chain transfer agents and their use in the synthesis of polymers | |
| DE69530512D1 (de) | Phosphatase-aktivierte quervernetzende konjugierende und reduzierende agenzien, verfahren unter verwendung solcher agenzien und reagenzien die phosphatase-aktivierte quervernetzende und konjugierende agenzien enthalten | |
| GR3004988T3 (fr) | ||
| NO178500C (no) | Spikamycinderivater, mellomprodukt samt antitumormiddel | |
| ATE155148T1 (de) | Höheres alpha-olefincopolymerisat, verfahren zu seiner herstellung, daraus hergestelltes vulkanisiertes produkt und vulkanisierbare gummizusammensetzung | |
| DK318885D0 (da) | Polynukleotider, der er bundet kovalent til en fast baerer, fremgangsmaade til deres fremstilling samt anvendelsen heraf | |
| DE59309756D1 (de) | 4-Iminochinoline, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| MA23129A1 (fr) | Nouveaux derives de l'erythromycine,leur procede de preparatn et leur application | |
| DK0644196T3 (da) | TTTr som beskyttelsesgruppe i nucleotidsyntesen | |
| UA66748C2 (en) | Phenyl substituted 4-azasteroids fluroderivatives, methods for the preparation thereof (variants) and pharmaceutical composition based thereon | |
| SE8802574D0 (sv) | Oligonucleotide hybridization probes and means for the synthesis of the most preferred probes | |
| DE69600739D1 (de) | Salpetersäureester von 2-(2,6-Dihalophenylamino) Phenylacetoessigsäurederivaten und Verfahren zu ihrer Herstellung | |
| IL116971A0 (en) | 2r, 3r-epixyhex-5-en-1-ol useful as an intermediate in the asymmetric synthesis of 3-substituted furanoside compounds | |
| DE3768469D1 (de) | N-substituierte, estergruppen enthaltende acrylamide. | |
| ATE90692T1 (de) | Nichtwaesserige polymere dispersionen und verfahren zu deren herstellung. | |
| PT84158B (pt) | Processo para a preparacao de copolimeros de cloreto de vinilo | |
| ATE221920T1 (de) | Verwendung von silicium-haltigen terpolymeren zur fettenden ausrüstung von leder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 524997 Country of ref document: ES |